Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported: the quote is verbatim from the operative list in (e)(6), which is introduced by 'An advertisement for a prescription drug is false, lacking in fair balance, or otherwise misleading, or otherwise violative of section 502(n) of the act, among other reasons, if it:'. Item (ii) is therefore a binding per se violation, not an example, definition, or preamble commentary, and the rule statement ('comparative safety/effectiveness claim must be supported by substantial evidence or substantial clinical experience in that particular') is a faithful restatement.
- Locator is correct: the quoted sentence is (e)(6)(ii) of 21 CFR 202.1, distinct from the neighboring (e)(6)(i) (superiority claims generally, including vs. treatments) and (e)(6)(xvi) (differs-from/greater-potency claims).
- Authority correctly marked binding: 21 CFR 202.1 is a codified regulation, and (e)(6) states the listed content is violative of section 502(n).
- Determinism correctly marked judgment: both the trigger ('represents or suggests') and the test ('demonstrated ... by substantial evidence or substantial clinical experience') turn on impression and on adequacy of the evidence, not on literal presence/absence. The escalation trigger (disputed sufficiency of evidence) matches this.
- Atomic: safer-or-more-effective is a single substantiation requirement applied to one comparative claim; no independently checkable obligations are bundled.
- Severity 'blocker' is defensible: the paragraph declares such an advertisement false/misleading and violative of 502(n), i.e., not a cosmetic defect. Note the source does allow an FDA-granted written waiver of any provision of this paragraph, but that is an agency action, not a routing option for a reviewer, so it does not undercut the severity.
- Overstated on scope: the introductory sentence of (e)(6) limits these provisions to advertisements for prescription drugs. The rule as written ('For any comparative claim ...', applies_when = promotional generally) reaches OTC materials and non-advertising promotional labeling, which this excerpt does not establish. Also, (e)(6)(ii) is specifically a drug-to-drug comparison ('than another drug'); comparisons to non-drug treatments fall under (e)(6)(i), and the check's unqualified 'any comparative claim' blurs that line even though the rule statement gets it right.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — pass
claude-opus-5 · 2026-09-21
Reviewer's reasons
- The quote is verbatim from the operative list in 21 CFR 202.1(e)(6), whose chapeau states that 'An advertisement for a prescription drug is false, lacking in fair balance, or otherwise misleading, or otherwise violative of section 502(n) of the act ... if it:' — so clause (ii) is an operative prohibition, not an example, definition, or preamble summary. The rule statement (superiority comparison must be demonstrated in that particular by substantial evidence or substantial clinical experience) is a direct restatement.
- Not overstated: the regulation is mandatory in effect (the ad is deemed false/misleading and violative of 502(n)), so phrasing it as a 'must' is faithful. The rule also correctly self-limits to prescription drug advertising and expressly disclaims extension to OTC materials on this citation, which matches the scope of 202.1(e)(6).
- Atomic: a single checkable requirement — substantiation of a comparative superiority claim in the specific particular claimed. The cross-reference to (e)(6)(i) in the check is routing guidance for the correct locator, not a second independent obligation, and it is consistent with the source, since (e)(6)(i) covers superiority representations 'whether or not such representations are made by comparison with other drugs or treatments.'
- Determinism 'judgment' is right: whether the evidence is 'substantial' and whether it maps to the exact particular claimed, and whether copy 'suggests' superiority, all turn on evaluative reading rather than presence/absence of a literal string.
- Authority 'binding' is right — this is a codified FDA regulation, and the locator 21 CFR 202.1(e)(6)(ii) exactly matches the quoted clause in the source text.
- Severity 'blocker' is defensible: the provision deems the advertisement false/misleading and violative of section 502(n), i.e., a misbranding exposure, not a stylistic defect.
- applies_when ('promotional') is not invented and is narrower than the rule would otherwise be; the prescription-drug-advertisement limit is carried explicitly in the rule statement itself, so the scope limit from the source is not lost. Minor, non-blocking observations only: the check's phrase 'another named or identifiable drug' is slightly tighter than the regulation's 'another drug' (implied or class-level comparators are also captured by 'represents or suggests'), and the source's waiver mechanism (written FDA waiver on petition) is not mentioned — neither changes the substance of what a reviewer would check.